Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer

@article{Lockhart2006PhaseIS,
  title={Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer},
  author={A Craig Lockhart and Gillian F. Cropp and Jordan D. Berlin and Edwin F. Donnelly and Robert D Schumaker and Larry J. Schaaf and Kenneth R. Hande and Arthur C. Fleischer and Alison L. Hannah and Mace L. Rothenberg},
  journal={American Journal of Clinical Oncology},
  year={2006},
  volume={29},
  pages={109-115}
}
Objectives:Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer. Methods:SU5416 (85 or 145 mg/m2) was administered twice weekly throughout a 6-week period along with standard IFL (4 weeks on/2 weeks off). Plasma samples were assayed for SU5416, irinotecan… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
25 Citations
Background Citations
6
Methods Citations
1

25 Citations

Citation Type

Citation Type

Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors
TLDR
The plasma pharmacokinetics of SU5416 in children was similar to previously reported findings in adult cancer patients and the most serious drug‐related toxicities were grade 3 liver enzyme abnormalities, arthralgia, and hallucinations.
Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.
TLDR
HT associated with bevacizumab therapy is a manageable toxicity with the use of ACE-I, which resulted in better HT control than ACE-II, calcium channel or beta antagonists.
Expert Review of Clinical Pharmacology
TLDR
The development of bevacizumab as a monoclonal antibody targeting the VEGF pathway improved progression-free survival and overall survival in the metastatic settings, with no improvement in disease-free or overall survivalIn the adjuvant settings.
Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer.
Regorafenib: from bench to bedside in colorectal cancer
TLDR
The development of bevacizumab as a monoclonal antibody targeting the VEGF pathway improved progression-free survival and overall survival in the metastatic settings, with no improvement in disease-free or overall survivalIn the adjuvant settings.
Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer
TLDR
Genetic profiling regarding mechanisms of chemoresistance are needed to carry out individualized prediction of the lack of effectiveness of pharmacological regimens, to minimize side effects and prevent the selection of aggressive, cross-resistant clones.
Angiogenic molecular signature in colorectal cancer: Pharmacogenomic implications for the use of antiangiogenic therapies
TLDR
Findings are in agreement with the reported roles for both cytokines inflammatory and angiogenesis mediators in colorectal cancer.
VEGF inhibitors and prostate cancer therapy.
TLDR
The major angiogenic signaling pathway involving VEGF in prostate cancer progression and the role of various promising agents that targets this pathway are discussed.
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology
TLDR
Comparing selectively targeted tyrosine kinase inhibitors with a single target, multiple-targeted TKI within a single pathway and TKI with an extended spectrum of targets from more than a single pathways concluded that the greater number of targets produces a greater clinical benefit.
What is the risk of intracranial bleeding during anti-VEGF therapy?
TLDR
It is concluded that there is no trial evidence that anti-VEGF therapy confers an increased risk of intracranial bleeding, even in the presence of CNS metastases, and future trials of anti-veGF therapy should not exclude patients with controlled CNS metastase at enrollment.
...
...

References

SHOWING 1-10 OF 41 REFERENCES
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
  • M. Ducreux, M. Ychou, P. Rougier
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
The biweekly CPT-11/LV5FU2 combination is feasible and safe, without overlapping toxicity.
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
TLDR
Higher baseline levels of urine VEGF were observed in the 4 patients who gained clinical benefit, suggesting this may be a useful marker for predicting response to anti-VEGF therapies, suggesting that a weekly schedule of SU5416 shows signs of biological activity and is well tolerated at doses up to 145 mg/m(2).
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
TLDR
The addition of CPT-11 to 5-FU24h/LV seems to improve the therapeutic efficacy in terms of tumor response with manageable toxicity, and the recommended doses for further studies are C PT-11 80 mg/m2, LV 500 mg/ m2, and 5-fu24h 2.6 g/m3 given on a weekly-times-six schedule followed by a 1-week rest period.
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
  • B. Kuenen, L. Rosen, G. Giaccone
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Analysis of variables of the coagulation cascade and of vessel wall activation was performed in three patients and showed significant increases in thrombin generation and endothelial cell perturbation in a treatment cycle-dependent manner.
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
  • R. Goldberg, D. Sargent, S. Alberts
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe and should be considered as a standard therapy for patients with advanced colorectal cancer.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
TLDR
The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
TLDR
Correlative studies suggest that VEGF receptor or KIT inhibition was incomplete in at least some cases, providing a possible explanation for the observed lack of activity against advanced soft tissue sarcoma.
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
TLDR
Close clinical monitoring, early recognition of toxicities and toxicity syndromes, aggressive therapeutic intervention, and withholding therapy in the presence of unresolved drug-related toxicities is recommended for patients receiving IFL or other intensive chemotherapy regimens.
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
TLDR
Data indicate that half of the dose in urine and feces may constitute some further unknown nonextractable or nonfluorescent metabolites of the antitumor camptothecine derivative irinotecan, and should be of importance as a guide to further therapeutic evaluation of this drug.
...
...